ÂÜÀòÂÒÂ×

As Chief Commercial Officer at Enzyvant, Johanna Rossell provides overall strategic commercial direction for the company. Johanna leads both the U.S. commercial activities for RETHYMIC®, including marketing, market access and patient support initiatives, as well as pre-launch commercialization planning for rodatristat ethyl, including strategic cross-functional planning and engagement with payers and other key stakeholders. She also provides leadership for Enzyvant’s growth strategies such as expansions into new geographies, additional indications for the company’s regenerative technology and new assets.

Johanna has a broad and deep background across consumer goods and healthcare categories in the U.S. and several geographies around the world. She has led multifunctional teams delivering strong business results for companies such as Procter & Gamble, Novartis, Merck, Mallinckrodt and Biogen. She has had extensive success leading new products to the U.S. market and creating integrated pre- and post-launch commercial plans, both in the U.S. and globally, including a Regenerative Medicine Advanced Therapy (RMAT)-designated tissue-based product and several therapies for rare diseases.

Johanna received a Bachelor of Science in Computer Engineering and an MBA from Simon Bolivar University in Caracas, Venezuela.